Finerenone reduces cardiovascular and kidney disease risk in type 2 diabetes
May 16, 2026
Highly relevant
Outcomes:
Strength:
Diabetic Kidney Disease: Evidence-Based Treatments and Outcomes
Evidence related to diabetic kidney disease
Evidence related to diabetic kidney disease, albuminuria, kidney function, nephropathy progression, end-stage renal disease, and kidney-protective diabetes treatments.
8
Studies
13
Evidence Pairs
Moderate Research Support
Relationship Confidence: 55/100
Supporting Studies
8
Research documents analyzed
Evidence Pairs
13
Intervention-outcome relationships
Latest Publication
Jun 2026
Avg. Evidence: 45/100
Evidence Snapshot
Qualitative overview of the evidence landscape
Moderate Confidence
Practical Questions
Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) improve albuminuria?
intervention effectivenessEmerging Evidence
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Albuminuria.
Consistency: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Emerging | score 58.8 | strong positive | Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) improve composite renal outcomes (kidney failure, sustained egfr decline ≥57%, renal death)?
intervention effectivenessEmerging Evidence
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Composite renal outcomes (kidney failure, sustained eGFR decline ≥57%, renal death).
Consistency: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Emerging | score 58.8 | strong positive | Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Dapagliflozin improve urinary albumin-to-creatinine ratio?
intervention effectivenessEmerging Evidence
Dapagliflozin may improve Urinary albumin-to-creatinine ratio.
Consistency: Results are consistent across studies.
Ranked evidence signals
- 1
Dapagliflozin
Emerging | score 51.7 | moderate positive | Consistent | 2 studies
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Dapagliflozin improve estimated glomerular filtration rate?
intervention effectivenessEmerging Evidence
Dapagliflozin appears to improve Estimated glomerular filtration rate.
Consistency: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Dapagliflozin
Emerging | score 55.0 | strong positive | Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Dapagliflozin reduce renal and urinary disorders incidence?
intervention effectivenessEmerging Evidence
Dapagliflozin appears to improve Renal and urinary disorders incidence.
Consistency: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Dapagliflozin
Emerging | score 60.0 | strong positive | Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Pentoxifylline improve albuminuria?
intervention effectivenessEmerging Evidence
Pentoxifylline appears to improve Albuminuria.
Consistency: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Pentoxifylline
Emerging | score 53.0 | strong positive | Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Empagliflozin improve urinary albumin-to-creatinine ratio?
intervention effectivenessLimited Evidence
Current evidence does not show a clear benefit of Empagliflozin for Urinary albumin-to-creatinine ratio.
Consistency: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Empagliflozin
Limited | score 34.2 | neutral | Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Metformin improve estimated glomerular filtration rate?
intervention effectivenessLimited Evidence
Current evidence does not show a clear benefit of Metformin for Estimated glomerular filtration rate.
Consistency: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Metformin
Limited | score 40.0 | neutral | Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Studied interventions
Interventions studied in relation to this topic
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
1 study
View evidence
Dapagliflozin
2 studies
View evidence
Pentoxifylline
1 study
View evidence
Metformin
1 study
View evidence
Empagliflozin
1 study
View evidence
Integrated multidisciplinary diabetes and kidney care program
1 study
View evidence
Note: Scores are provided by the evidence graph and may reflect evidence strength, evidence base, or relationship confidence depending on context. Click any option to explore the supporting research in our archive.
Strongest evidence signals
Key patterns and insights identified across the research landscape
Strong positive signal
Dapagliflozin shows strong evidence for improving Renal and urinary disorders incidence
Dapagliflozin → Renal and urinary disorders incidence
Across 1 study, Dapagliflozin shows a strong positive signal for Renal and urinary disorders incidence.
1 studies
Strong positive signal
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) shows strong evidence for improving Albuminuria
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Albuminuria
Across 1 study, Finerenone (nonsteroidal mineralocorticoid receptor antagonist) shows a strong positive signal for Albuminuria.
1 studies
Strong positive signal
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) shows strong evidence for improving Composite renal outcomes (kidney failure, sustained eGFR decline ≥57%, renal death)
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Composite renal outcomes (kidney failure, sustained eGFR decline ≥57%, renal death)
Across 1 study, Finerenone (nonsteroidal mineralocorticoid receptor antagonist) shows a strong positive signal for Composite renal outcomes (kidney failure, sustained eGFR decline ≥57%, renal death).
1 studies
Strong positive signal
Dapagliflozin shows strong evidence for improving Estimated glomerular filtration rate
Dapagliflozin → Estimated glomerular filtration rate
Across 1 study, Dapagliflozin shows a strong positive signal for Estimated glomerular filtration rate.
1 studies
Strong positive signal
Pentoxifylline shows strong evidence for improving Albuminuria
Pentoxifylline → Albuminuria
Across 1 study, Pentoxifylline shows a strong positive signal for Albuminuria.
1 studies
Supporting Research
Selected studies that best represent the evidence behind this topic.
Semaglutide with Insulin Improves Diabetes Control and Kidney Health
High quality
Interventions:
Outcomes:
Strength:
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes
May 16, 2026
High quality
Interventions:
Strength:
Dapagliflozin may improve RAAS markers in diabetes patients
High quality
Interventions:
Strength:
Lifestyle changes may improve diabetes remission rates
High quality
Interventions:
Strength:
IDegLira improves long-term health outcomes and reduces costs for diabetes patients
High quality
Interventions:
Strength:
Click any study to view the full research summary, or click interventions and outcomes to filter the archive.
Related Evidence Topics
Explore related evidence areas connected by shared studies, interventions, or outcomes.
Explore all supporting studies
Browse the complete evidence archive for this topic, including interventions, outcomes, and related research. Use powerful filters to find exactly what you're looking for.
View All Supporting StudiesFilter by study type, publication date, effect size, and more to refine your research